- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Approval leads to procurement process initiation.
2 reports, 1 independent
Updated Wed 00:00
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Approval leads to procurement process initiation.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.
- Veradermics, Incorporated is seeking federal regulatory approval from the FDA for its drug candidates.
- Oversight failures and regulatory inertia in the U.S. drug approval process were exposed on August 3rd, involving the FDA and Merck.
The entities involved
Related events
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.